Base de dados : MEDLINE
Pesquisa : D03.132.327.412.250 [Categoria DeCS]
Referências encontradas : 964 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 97 ir para página                         

  1 / 964 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27037980
[Au] Autor:Sharaf El-Din MM; Nassar MW; Attia KA; Demellawy MA; Kaddah MM
[Ad] Endereço:Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Mansoura University, Dakahlia, Egypt.
[Ti] Título:Validated liquid chromatography-tandem mass spectrometry method for simultaneous determination of clopamide, reserpine and dihydroergotoxine: Application to pharmacokinetics in human plasma.
[So] Source:J Pharm Biomed Anal;125:236-44, 2016 Jun 05.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A simple, sensitive and rapid high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated for the simultaneous quantitation of clopamide, reserpine and dihydroergotoxine (ergoloid mesylates) in human plasma. Under basic conditions, liquid-liquid extraction using ethyl acetate was efficiently used for extraction of the analytes from plasma samples in presence of indapamide as internal standard (IS). The analytes were separated with isocratic elution on Phenomenex(®) Synergi Fusion-RP 80A column (50×4.6mm, 4µm). With positive ion electrospray ionization (ESI), the analytes were quantified and monitored on a triple quadrupole mass spectrometer using Multiple Reaction Monitoring (MRM) scanning mode. Satisfactory results regarding linearity, recovery, stability, accuracy and precision of the analytes were obtained. The method was linear in the concentration range of 0.04-30.00ng/mL for reserpine, 1-96.00ng/mL for clopamide, and 0.05-40.00ng/mL for dihydroergotoxine alkaloids, respectively. For all analytes, the high sensitivity of HPLC-MS/MS method revealed sufficient lower limit of quantification (LLOQ) ranged from 0.04-1ng/mL using 1mL of plasma. The recoveries from spiked control samples were ≥86.16% for all analytes and IS. The intra- and inter-day precision variations were lower than 13.03% while the accuracy values ranged from 91.76% to 111.50%. The developed method was successfully applied to pharmacokinetic study of fixed dose combination of clopamide, reserpine and dihydroergotoxine in healthy male volunteers.
[Mh] Termos MeSH primário: Cromatografia Líquida/métodos
Clopamida/sangue
Di-Hidroergotoxina/sangue
Reserpina/sangue
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Clopamida/farmacocinética
Di-Hidroergotoxina/farmacocinética
Seres Humanos
Limite de Detecção
Reprodutibilidade dos Testes
Reserpina/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
11032-41-0 (Dihydroergotoxine); 17S83WON0I (Clopamide); 8B1QWR724A (Reserpine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170411
[Lr] Data última revisão:
170411
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160403
[St] Status:MEDLINE


  2 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25591512
[Au] Autor:Levin OS; Barantsevich ER; Belskaya GN; Vasenina EE; Kopishinskaya SV; Lukashevich IG; Ostroumova OD; Psokhina OV; Radiuk MA
[Ti] Título:[Efficacy of the combination drug vasobral in chronic vascular encephalopathy].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;114(10):25-9, 2014.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:OBJECTIVE: Despite the high prevalence of chronic vascular encephalopathy, its diagnosis and treatment remain understudied. This observational multicenter trial assessed the efficacy and safety of vasobral in patients with cerebral ischemia. MATERIAL AND METHODS: The open observational study was carried out in 37 centers in 11 Russian cities and included 300 patients with confirmed diagnosis of chronic vascular encephalopathy, stages 1 and 2, without dementia. The patients received 1 tablet (4 mg α-dihydroergocryptine and 40 mg caffeine) 2 times a day during 3 months. RESULTS AND CONCLUSION: There was an improvement of cognitive and affective status as well as quality of life and a decrease of subjective signs of chronic vascular encephalopathy. Vasobral did not cause significant fluctuations of arterial pressure and was safe for patients with chronic vascular encephalopathy and arterial hypertension.
[Mh] Termos MeSH primário: Dano Encefálico Crônico/tratamento farmacológico
Isquemia Encefálica/tratamento farmacológico
Cafeína/uso terapêutico
Doenças de Pequenos Vasos Cerebrais/tratamento farmacológico
Di-Hidroergotoxina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Cafeína/efeitos adversos
Di-Hidroergotoxina/efeitos adversos
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Drug Combinations); 11032-41-0 (Dihydroergotoxine); 3G6A5W338E (Caffeine); 94423-99-1 (Vasobral)
[Em] Mês de entrada:1503
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150117
[St] Status:MEDLINE


  3 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23528488
[Au] Autor:Kamchatnov PR
[Ti] Título:[Vasobral in the treatment of brain lesions: views of physicians and patients].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;113(1):23-5, 2013.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:A study was based on the survey of 419 neurologists and 1189 their patients with different forms of cerebrovascular diseases using a specially developed questionnaire. In most cases, vasobral was used as a monotherapy or in a complex treatment. Twenty-two percent of physicians reported that vasobral was the most effective compared to other drugs. The good tolerability of treatment (18%) and the broad spectrum of indications and clinical effects (17%) were reported as well. The large percentage (75%) of patients indicated the positive effect of vasobral on memory, reasoning, vertigo etc The maximal effect was identified in the treatment of mild cognitive impairment caused by chronic brain ischemia and vertebrobasilar insufficiency. Vasobral is recommended for a use in a complex therapy in patients with more severe brain lesions and cognitive deficit.
[Mh] Termos MeSH primário: Cafeína/uso terapêutico
Transtornos Cerebrovasculares/tratamento farmacológico
Di-Hidroergotoxina/uso terapêutico
[Mh] Termos MeSH secundário: Transtornos Cerebrovasculares/complicações
Cognição/efeitos dos fármacos
Transtornos Cognitivos/tratamento farmacológico
Transtornos Cognitivos/etiologia
Combinação de Medicamentos
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Memória/efeitos dos fármacos
Pacientes
Médicos
Inquéritos e Questionários
Vertigem/tratamento farmacológico
Vertigem/etiologia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 11032-41-0 (Dihydroergotoxine); 3G6A5W338E (Caffeine); 94423-99-1 (Vasobral)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130327
[St] Status:MEDLINE


  4 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22441761
[Au] Autor:Radosavljevic M; Pajovic B; Radunovic M; Radojevic N; Bjelogrlic B
[Ad] Endereço:Department of Forensic Medicine, Clinical Centre of Montenegro, 2000 Podgorica, Ljubljanska 1, Montenegro.
[Ti] Título:Influence of dihydroergotoxine, bromocriptine, and ergotamine on penile erection in Wistar rats.
[So] Source:J Androl;33(5):866-71, 2012 Sep-Oct.
[Is] ISSN:1939-4640
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The pilot study presented was conducted to determine as to whether ergot alkaloids (alpha-adrenergic blockers) have a potential effect on penile erectile function. The influence of dihydroergotoxine, bromocriptine, and ergotamine was studied on the erection ability in intact, two-grade outbred male Wistar albino rats that were out of their estrous phase. The experimental animals were injected intrapenially with the substances under examination: dihydroergotoxine mesylate (0.1 mg/0.1 mL, 0.3 mg/0.1 mL, and 1 mg/0.1 mL), bromocriptine mesylate (0.3 mg/0.1 mL, 1 mg/0.1 mL, and 3 mg/0.1 mL), and ergotamine tartrate (0.1 mg/0.1 mL, 0.3 mg/0.1 mL, and 1mg/0.1 mL). Every dose was tested on a pattern of 30 rats. These mentioned substances were injected in the amount of 1 mm to the left of the proximal part of the superficial dorsal vein of the penis, in the region of the penis root. After injection, the animals were then observed within the next 90 minutes. In the trial, the following was observed: the number of rats with an erection achieved, the period of time from intrapenial application to the appearance of the first erection, and the duration of the erection. Ultimately, the research results confirm the efficiency of dihydroergotoxine and bromocriptine as erectogenic agents, as well as ergotamine as a detumescent compared with saline solutions.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos alfa/farmacologia
Bromocriptina/farmacologia
Di-Hidroergotoxina/farmacologia
Ergotamina/farmacologia
Ereção Peniana/efeitos dos fármacos
Pênis/efeitos dos fármacos
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/administração & dosagem
Animais
Bromocriptina/administração & dosagem
Di-Hidroergotoxina/administração & dosagem
Relação Dose-Resposta a Droga
Ergotamina/administração & dosagem
Injeções Intravenosas
Masculino
Pênis/irrigação sanguínea
Projetos Piloto
Ratos
Ratos Wistar
Tempo de Reação
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 11032-41-0 (Dihydroergotoxine); 3A64E3G5ZO (Bromocriptine); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1303
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120324
[St] Status:MEDLINE


  5 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22500318
[Au] Autor:Kamchatnov PR
[Ti] Título:[The use of vasobral in patients with chronic cerebrovascular disorders].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;111(10 Pt 1):70-2, 2011.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Mh] Termos MeSH primário: Cafeína/administração & dosagem
Transtornos Cerebrovasculares/tratamento farmacológico
Di-Hidroergotoxina/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Doença Crônica
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Drug Combinations); 11032-41-0 (Dihydroergotoxine); 3G6A5W338E (Caffeine); 94423-99-1 (Vasobral)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120414
[St] Status:MEDLINE


  6 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21389936
[Au] Autor:Tabeeva GR; Azimova IuE
[Ti] Título:[Preventive treatment of migraine with vasobral: a multicenter trial].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;110(11 Pt 2):26-30, 2010.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The results of an open prospective trial on the treatment of migraine with vasobral which was conducted in 170 medical centers (27 cities) of the Russian Federation are summarized. The trial included 5475 patients treated with vasobral in dosage 2 ml (1 ml contains 1 mg of alpha-dihydroergocryptine and 10 mg of caffeine) twice a day during 2 months. Assessment criteria of treatment efficacy were frequency and duration of migraine seizures, pain syndrome severity, presence of concomitant syndromes, general state and working capacity of patients and side-effects. Vasobral was effective and safe medication for the prevention of migraine. Its preventive effect is due to the decrease of frequency and duration of migraine seizures, pain severity and to the overall improvement of patient's state. Vasobral can be recommended to many migraine patients, in particular to those in the young age and with short disease duration.
[Mh] Termos MeSH primário: Cafeína/uso terapêutico
Di-Hidroergotoxina/uso terapêutico
Transtornos de Enxaqueca/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Transtornos de Enxaqueca/fisiopatologia
Estudos Prospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Drug Combinations); 11032-41-0 (Dihydroergotoxine); 3G6A5W338E (Caffeine); 94423-99-1 (Vasobral)
[Em] Mês de entrada:1103
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110311
[St] Status:MEDLINE


  7 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:20614656
[Au] Autor:Zaitseva IN
[Ti] Título:[Use of vasobral in therapy of central nervous system pathology in children of early age].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;110(1):92-4, 2010.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Mh] Termos MeSH primário: Cafeína/uso terapêutico
Doenças do Sistema Nervoso Central/tratamento farmacológico
Di-Hidroergotoxina/uso terapêutico
Desempenho Psicomotor/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Oral
Cafeína/administração & dosagem
Doenças do Sistema Nervoso Central/fisiopatologia
Pré-Escolar
Di-Hidroergotoxina/administração & dosagem
Relação Dose-Resposta a Droga
Combinação de Medicamentos
Seguimentos
Seres Humanos
Lactente
Desempenho Psicomotor/fisiologia
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 11032-41-0 (Dihydroergotoxine); 3G6A5W338E (Caffeine); 94423-99-1 (Vasobral)
[Em] Mês de entrada:1007
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100710
[St] Status:MEDLINE


  8 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19529847
[Au] Autor:Berezina TP; Ovsyannikov VI
[Ad] Endereço:Laboratory for Physiology of Digestion, Department for Physiology of Visceral Systems, Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia.
[Ti] Título:Mechanism for the inhibition of contractile activity of the gastric antrum and pylorus in rabbits during psychogenic stress.
[So] Source:Bull Exp Biol Med;147(3):296-300, 2009 Mar.
[Is] ISSN:1573-8221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Psychogenic stress in rabbits (fixation to a frame) was accompanied by the inhibition of contractile activity of the gastric antrum and pylorus. These changes persisted during blockade of muscarinic receptors, nicotinic receptors, alpha(2)-adrenoceptors, and beta(1)/beta(2) adrenoceptors. A stress-induced decrease in gastric motor activity was mediated by the nonadrenergic noncholinergic mechanism. It resulted from the influence of a hormonal stress factor on the stomach, which was probably realized through nonadrenergic inhibitory neurons of the enteric nervous system.
[Mh] Termos MeSH primário: Antro Pilórico/fisiopatologia
Piloro/fisiopatologia
Estresse Psicológico/fisiopatologia
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 2
Antagonistas Adrenérgicos alfa/farmacologia
Antagonistas Adrenérgicos beta/farmacologia
Animais
Di-Hidroergotoxina/farmacologia
Bloqueadores Ganglionares/farmacologia
Motilidade Gastrointestinal/efeitos dos fármacos
Motilidade Gastrointestinal/fisiologia
Compostos de Hexametônio/farmacologia
Masculino
Antagonistas Muscarínicos/farmacologia
Contração Muscular/efeitos dos fármacos
Contração Muscular/fisiologia
Músculo Liso/fisiopatologia
Oxifenônio/farmacologia
Propranolol/farmacologia
Antro Pilórico/efeitos dos fármacos
Piloro/efeitos dos fármacos
Coelhos
Receptores Adrenérgicos beta/metabolismo
Receptores Muscarínicos/metabolismo
Receptores Nicotínicos/metabolismo
Ioimbina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-2 Receptor Antagonists); 0 (Adrenergic alpha-Antagonists); 0 (Adrenergic beta-Antagonists); 0 (Ganglionic Blockers); 0 (Hexamethonium Compounds); 0 (Muscarinic Antagonists); 0 (Receptors, Adrenergic, beta); 0 (Receptors, Muscarinic); 0 (Receptors, Nicotinic); 11032-41-0 (Dihydroergotoxine); 2Y49VWD90Q (Yohimbine); 9Y8NXQ24VQ (Propranolol); D2G5508Y7I (Oxyphenonium); V26UVZ0360 (benzohexonium)
[Em] Mês de entrada:0910
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090617
[St] Status:MEDLINE


  9 / 964 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18607852
[Au] Autor:Abdul M; Mccray SD; Hoosein NM
[Ad] Endereço:Department of Biology, Claflin University, Orangeburg, SC 29115, USA.
[Ti] Título:Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer.
[So] Source:Acta Oncol;47(8):1546-50, 2008.
[Is] ISSN:1651-226X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In prostate cancer, gamma-aminobutyric acid (GABA) has been previously reported to increase cellular proliferation via the ionotropic GABAa receptor (GABAar) and to promote cellular invasiveness via the metabotropic GABAb receptor. METHODS: In this study, we have investigated, by immunohistochemistry, GABAar levels in 12 normal human prostate, 13 benign prostatic hyperplasia (BPH) and 148 human prostate cancer specimens. We have also examined the effect of several GABA agonists and antagonists on the in vitro proliferation of four human prostate cancer cell lines: LNCaP, MDA-PCA-2b, DU145 and PC3. RESULTS: GABAar immunoreactivity was present in the stroma of ~75% of the normal and BPH specimens, and in 95% of the prostate cancer specimens. Also, low to moderate GABAar staining was observed in the acinar epithelium of 50 (33%) prostate cancer specimens. No correlation was observed between GABAar staining and patient age, Gleason Sum or TNM stage. A GABAa agonist isoguvacine, at doses between 5-50 microg/ml (31-310 microM), stimulated the proliferation of all four human prostate cancer cell lines, tested. Baclofen, a GABAb agonist (up to 50 microg/ml, 234 microM) had no effect on growth. Also, at concentrations up to 100 microg/ml, GABA antagonists, bicuculline (223 microM), picrotoxin (166 microM) and saclofen (400 microM), did not have significant growth-inhibitory effects. However, dihydroergotoxine, which binds the GABAar chloride ion-channel, inhibited cellular proliferation (IC(50) 18-38 microM). CONCLUSIONS: These data indicate frequent expression of GABAar in prostate cancer and support a role for GABAar in the proliferation of prostate cancer cells.
[Mh] Termos MeSH primário: Neoplasias da Próstata/metabolismo
Receptores de GABA-A/metabolismo
[Mh] Termos MeSH secundário: Bicuculina/farmacologia
Proliferação Celular/efeitos dos fármacos
Neoplasias do Colo/metabolismo
Neoplasias do Colo/patologia
Di-Hidroergotoxina/farmacologia
Agonistas GABAérgicos/farmacologia
Antagonistas GABAérgicos/farmacologia
Agonistas de Receptores de GABA-A
Agonistas dos Receptores de GABA-B
Seres Humanos
Ácidos Isonicotínicos/farmacologia
Masculino
Picrotoxina/farmacologia
Próstata/metabolismo
Próstata/patologia
Hiperplasia Prostática/metabolismo
Hiperplasia Prostática/patologia
Neoplasias da Próstata/patologia
Receptores de GABA-B/metabolismo
Células Tumorais Cultivadas
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (GABA Agonists); 0 (GABA Antagonists); 0 (GABA-A Receptor Agonists); 0 (GABA-B Receptor Agonists); 0 (Isonicotinic Acids); 0 (Receptors, GABA-A); 0 (Receptors, GABA-B); 11032-41-0 (Dihydroergotoxine); 124-87-8 (Picrotoxin); Y37615DVKC (Bicuculline); YTF580771Y (isoguvacine)
[Em] Mês de entrada:0812
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080709
[St] Status:MEDLINE
[do] DOI:10.1080/02841860801961265


  10 / 964 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:16252685
[Au] Autor:Berezina TP; Ovsiannikov VI
[Ti] Título:[Mechanisms of inhibition of the contractile activity in the ileo-caecal zone in rabbits under psychogenic stress].
[So] Source:Ross Fiziol Zh Im I M Sechenova;91(8):893-902, 2005 Aug.
[Is] ISSN:0869-8139
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:In experiments on unanaesthetized rabbits, myoelectric activity (contractile activity index) of distal ileum, caecum, and proximal colon in two sites was studied under stress induced by fastening a rabbit to the table in supine position. The stress caused sharp decrease (up to complete disappearance) of the contractile activity in all studied compartments of the ileocaecal intestine with partial or complete restoration after release of the animal. Nonselective blockade of pre- and postsynaptic alpha-adrenoceptor with dihydroergotoxin abolished the initial component of the specified inhibitory response. The latter was caused by "adrenergic inhibition" as a result of action of catecholamines circulating in blood on inhibitory smooth muscle alpha-adrenoceptor. Against the background of muscarinic cholinoceptor blockade, the stressor inhibition of ileocaecal contractile activity observed in control experiments was completely preserved. The periods of supression of ileoceacal contractile activity under stress resistant to blockade of alpha-, beta-adrenoceptor and muscarinic cholinoceptor, are caused by the mechanism of "nonadrenergic noncholinergic inhibition", which is realized at the expence of activation of the enteric inhibitory neurones.
[Mh] Termos MeSH primário: Ceco/fisiologia
Colo/fisiologia
Íleo/fisiologia
Músculo Liso/fisiologia
Estresse Psicológico/fisiopatologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/farmacologia
Antagonistas Adrenérgicos beta/farmacologia
Animais
Ceco/efeitos dos fármacos
Colo/efeitos dos fármacos
Di-Hidroergotoxina/farmacologia
Motilidade Gastrointestinal/efeitos dos fármacos
Motilidade Gastrointestinal/fisiologia
Íleo/efeitos dos fármacos
Masculino
Antagonistas Muscarínicos/farmacologia
Contração Muscular/efeitos dos fármacos
Músculo Liso/efeitos dos fármacos
Oxifenônio/farmacologia
Propranolol/farmacologia
Coelhos
Receptores Adrenérgicos alfa/efeitos dos fármacos
Receptores Adrenérgicos alfa/fisiologia
Receptores Adrenérgicos beta/efeitos dos fármacos
Receptores Adrenérgicos beta/fisiologia
Restrição Física
Estresse Psicológico/etiologia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Adrenergic beta-Antagonists); 0 (Muscarinic Antagonists); 0 (Receptors, Adrenergic, alpha); 0 (Receptors, Adrenergic, beta); 11032-41-0 (Dihydroergotoxine); 9Y8NXQ24VQ (Propranolol); D2G5508Y7I (Oxyphenonium)
[Em] Mês de entrada:0512
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:051029
[St] Status:MEDLINE



página 1 de 97 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde